vs
费森尤斯医疗（FMS）与林德（LIN）财务数据对比。点击上方公司名可切换其他公司
林德的季度营收约是费森尤斯医疗的1.6倍（$8.8B vs $5.5B），林德净利率更高（17.5% vs 7.9%，领先9.5%），林德同比增速更快（5.8% vs -0.3%）
费森尤斯医疗是德国知名医疗保健企业，核心业务为肾脏透析服务，在全球运营4171家门诊透析中心，服务约34.54万名患者。公司主要为终末期肾病患者提供治疗服务，该类患者需终身每周接受3次透析治疗以维持生命。
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
FMS vs LIN — 直观对比
营收规模更大
LIN
是对方的1.6倍
$5.5B
营收增速更快
LIN
高出6.1%
-0.3%
净利率更高
LIN
高出9.5%
7.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.5B | $8.8B |
| 净利润 | $434.2M | $1.5B |
| 毛利率 | 27.4% | — |
| 营业利润率 | 11.7% | 23.0% |
| 净利率 | 7.9% | 17.5% |
| 营收同比 | -0.3% | 5.8% |
| 净利润同比 | 240.4% | -11.3% |
| 每股收益（稀释后） | — | $3.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FMSLIN
| Q4 25 | $5.5B | $8.8B | ||
| Q3 25 | — | $8.6B | ||
| Q2 25 | — | $8.5B | ||
| Q1 25 | — | $8.1B | ||
| Q4 24 | $5.5B | $8.3B | ||
| Q3 24 | — | $8.4B | ||
| Q2 24 | — | $8.3B | ||
| Q1 24 | — | $8.1B |
净利润FMSLIN
| Q4 25 | $434.2M | $1.5B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.8B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | $127.6M | $1.7B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.6B |
毛利率FMSLIN
| Q4 25 | 27.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率FMSLIN
| Q4 25 | 11.7% | 23.0% | ||
| Q3 25 | — | 27.5% | ||
| Q2 25 | — | 27.7% | ||
| Q1 25 | — | 26.9% | ||
| Q4 24 | 5.1% | 27.4% | ||
| Q3 24 | — | 25.0% | ||
| Q2 24 | — | 26.4% | ||
| Q1 24 | — | 25.9% |
净利率FMSLIN
| Q4 25 | 7.9% | 17.5% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 20.8% | ||
| Q1 25 | — | 20.6% | ||
| Q4 24 | 2.3% | 20.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 20.1% |
每股收益（稀释后）FMSLIN
| Q4 25 | — | $3.28 | ||
| Q3 25 | — | $4.09 | ||
| Q2 25 | — | $3.73 | ||
| Q1 25 | — | $3.51 | ||
| Q4 24 | — | $3.61 | ||
| Q3 24 | — | $3.22 | ||
| Q2 24 | — | $3.44 | ||
| Q1 24 | — | $3.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $5.1B |
| 总债务越低越好 | — | $20.7B |
| 股东权益账面价值 | $15.4B | $38.2B |
| 总资产 | $33.5B | $86.8B |
| 负债/权益比越低杠杆越低 | — | 0.54× |
8季度趋势，按日历期对齐
现金及短期投资FMSLIN
| Q4 25 | $1.7B | $5.1B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | — | $4.8B | ||
| Q1 25 | — | $5.3B | ||
| Q4 24 | $1.3B | $4.8B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $4.6B | ||
| Q1 24 | — | $4.8B |
总债务FMSLIN
| Q4 25 | — | $20.7B | ||
| Q3 25 | — | $18.6B | ||
| Q2 25 | — | $19.7B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | — | $15.3B | ||
| Q3 24 | — | $17.5B | ||
| Q2 24 | — | $16.9B | ||
| Q1 24 | — | $15.2B |
股东权益FMSLIN
| Q4 25 | $15.4B | $38.2B | ||
| Q3 25 | — | $38.6B | ||
| Q2 25 | — | $38.5B | ||
| Q1 25 | — | $38.0B | ||
| Q4 24 | $17.0B | $38.1B | ||
| Q3 24 | — | $39.2B | ||
| Q2 24 | — | $38.2B | ||
| Q1 24 | — | $38.8B |
总资产FMSLIN
| Q4 25 | $33.5B | $86.8B | ||
| Q3 25 | — | $86.0B | ||
| Q2 25 | — | $86.1B | ||
| Q1 25 | — | $82.7B | ||
| Q4 24 | $36.3B | $80.1B | ||
| Q3 24 | — | $82.5B | ||
| Q2 24 | — | $80.2B | ||
| Q1 24 | — | $80.3B |
负债/权益比FMSLIN
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.9B | $3.0B |
| 自由现金流经营现金流 - 资本支出 | — | $1.6B |
| 自由现金流率自由现金流/营收 | — | 17.9% |
| 资本支出强度资本支出/营收 | — | 16.6% |
| 现金转化率经营现金流/净利润 | 6.67× | 1.98× |
| 过去12个月自由现金流最近4个季度 | — | $5.1B |
8季度趋势，按日历期对齐
经营现金流FMSLIN
| Q4 25 | $2.9B | $3.0B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | $2.6B | $2.8B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $2.0B |
自由现金流FMSLIN
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | $954.0M | ||
| Q1 25 | — | $891.0M | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $796.0M | ||
| Q1 24 | — | $906.0M |
自由现金流率FMSLIN
| Q4 25 | — | 17.9% | ||
| Q3 25 | — | 19.4% | ||
| Q2 25 | — | 11.2% | ||
| Q1 25 | — | 11.0% | ||
| Q4 24 | — | 18.8% | ||
| Q3 24 | — | 19.9% | ||
| Q2 24 | — | 9.6% | ||
| Q1 24 | — | 11.2% |
资本支出强度FMSLIN
| Q4 25 | — | 16.6% | ||
| Q3 25 | — | 14.8% | ||
| Q2 25 | — | 14.8% | ||
| Q1 25 | — | 15.7% | ||
| Q4 24 | — | 15.1% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | 13.7% | ||
| Q1 24 | — | 12.9% |
现金转化率FMSLIN
| Q4 25 | 6.67× | 1.98× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | 20.20× | 1.63× | ||
| Q3 24 | — | 1.76× | ||
| Q2 24 | — | 1.16× | ||
| Q1 24 | — | 1.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FMS
暂无分部数据
LIN
| Other | $4.9B | 56% |
| Packaged Gas | $1.6B | 19% |
| Merchant | $1.2B | 14% |
| On Site | $950.0M | 11% |
| Other Distribution Methods | $64.0M | 1% |
